Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,902
  • Shares Outstanding, K 47,725
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,890 K
  • 60-Month Beta 2.43
  • Price/Sales 15.08
  • Price/Cash Flow N/A
  • Price/Book 1.07
Trade GLYC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.38
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -6.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.06 +0.95%
on 09/30/20
3.90 -20.79%
on 09/16/20
-0.68 (-18.06%)
since 08/28/20
3-Month
3.06 +0.95%
on 09/30/20
5.19 -40.48%
on 07/21/20
-0.67 (-17.85%)
since 06/30/20
52-Week
1.82 +69.73%
on 03/18/20
6.72 -54.03%
on 11/15/19
-1.22 (-28.33%)
since 09/30/19

Most Recent Stories

More News
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will present at the upcoming H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference taking place...

GLYC : 3.08 (-1.28%)
GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that on August 14, 2020 the compensation committee of the Company's Board of Directors approved the grant of non-qualified stock option...

GLYC : 3.08 (-1.28%)
New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemia...

GLYC : 3.08 (-1.28%)
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020 were...

GLYC : 3.08 (-1.28%)
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occlusive...

GLYC : 3.08 (-1.28%)
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry

GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GLYC : 3.08 (-1.28%)
GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation will...

GLYC : 3.08 (-1.28%)
GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR)...

GLYC : 3.08 (-1.28%)
GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the "Annual Meeting") will be held virtually instead of in person. Due to the ongoing public health impact...

GLYC : 3.08 (-1.28%)
GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were...

GLYC : 3.08 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

2nd Resistance Point 3.33
1st Resistance Point 3.22
Last Price 3.08
1st Support Level 3.06
2nd Support Level 3.01

See More

52-Week High 6.72
Fibonacci 61.8% 4.85
Fibonacci 50% 4.27
Fibonacci 38.2% 3.69
Last Price 3.08
52-Week Low 1.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar